Open Access Open Access  Restricted Access Subscription or Fee Access

Limitations to Therapeutic Approaches to T2DM in Light of Different HbA1C Values Suggested by Different Scientific Associations: A Review

Teja Sree Bitla, Ravishankar Polisetty, Purna Divya Singanamala, Shaik Aminabee

Abstract


The present article provided a comprehensive review of international and national guidelines for managing Type-2 diabetes, with a focus on personalized treatment strategies. It discussed the recommended glycated haemoglobin targets and the initial treatment approach involving lifestyle modifications and the use of metformin. The present article underlined the necessity for treatment intensification due to the progressive nature of type-2 diabetes. It also emphasized the complexity of selecting additional antidiabetic medications, which considers various patient-specific factors and the therapeutic characteristics of the drugs. Despite the presence of extensive treatment choices and established guidelines, it was emphasized that a considerable number of patients were unable to attain favourable metabolic control. The present article concluded with a discussion on the glucose utilization of different organs in conscious rat’s post-endotoxin treatment, illustrating the differential responses of various organs.

Keywords


Diabetic, HbA1C, hyperglycaemia, antidiabetic pharmacotherapy, insulin

Full Text:

PDF

References


Dansinger M. The Hemoglobin A1c test for diabetes. Diabetes Guide [Internet]; 2023 Mar 4. Available from: https://www.webmd.com/diabetes/glycated-hemoglobin-test-hba1c 2. American Diabetes Association. Standards of Medical Care in Diabetes-2018 Abridged for Primary Care Providers. Clin Diabetes. 2018; 36(1): 14–37p. doi: 10.2337/cd17-0119. PMID: 29382975; PMCID: PMC5775000.

Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovič L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F. American Association of Clinical Endocrinologists and American College of Endocrinology - Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan - 2015. Endocr Pract. 2015; 21 Suppl 1(Suppl 1): 1–87p. doi: 10.4158/EP15672.GL. PMID: 25869408; PMCID: PMC4959114.

Centers for Disease Control and Prevention. New CDC report: More than 100 million Americans have diabetes or prediabetes. USA: CDC; 2017. Available from: https://www.cdc.gov/media/ releases/2017/p0718-diabetes-report.html.

Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA; Clinical Guidelines Committee of the American College of Physicians; Fitterman N, Balzer K, Boyd C, Humphrey LL, Iorio A, Lin J, Maroto M, McLean R, Mustafa R, Tufte J. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med. 2018; 168(8): 569–576p. doi: 10.7326/M17-0939. Epub 2018 Mar 6. PMID: 29507945.

Nathan DM, Buse JB, Davidson MB, Ferranninni E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193–203p.

International Diabetes Federation. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Belgium: IDF; 2017. Available from: https://idf.org/media/uploads/2023/05/attachments-63.pdf (Accessed on 1 March 2017).

Turner RC; UK Prospective Diabetes Study Group (UKPDS 34). Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34). The Lancet. 1998; 352(9131): 854–865p. DOI: https://doi.org/10.1016/S0140-6736(98)07037-8.

Redmon B, Caccamo D, Flavin P, Michels R, O’Connor P, Roberts J, Smith S, Sperl-Hillen J. Diagnosis and Management of Type 2 Diabetes Mellitus in Adults, 16th Edition. Bloomington: Institute for Clinical Systems Improvement; 2014.

American Diabetes Association® deeply concerned about new guidance from American College of Physicians regarding blood glucose targets for people with type 2 diabetes. USA: American Diabetes Association; 2018 Mar 8. Available from: http://www.diabetes.org/newsroom/press-releases/2018/ada-acp-guidance-response.html (Accessed on March 25, 2018).

Viollet B, Guigas B, Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metfromin: an overview. Clin Sci (Lond). 2012; 122(6): 253–270p. doi:10.1042/ CS20110386

Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014; 312(24): 2668–2675p. doi:10.1001/ jama.2014.15298.

Fogelman Y, Kitai E, Blumberg G, Golan-Cohen A, Rapoport M, Carmeli E. Vitamin B12 screening in metformin-treated diabetics in primary care: were elderly patients less likely to be tested? Aging Clin Exp Res. 2016; 29(2): 135–139p. doi:10.1007/s40520-016-0546-1 14. Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, Wexler D, Lachin JM. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013; 36(8): 2254–2261p. doi:10.2337/dc13-0356

Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016; 4(6): 525–536p.

Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016; 164(11): 740–751p. doi:10.7326/M15-2650.

Harris KB, McCarty DJ. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015; 6(1): 3–18p. doi:10.1177/2042018814558242.

Riser TS, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2diabetes mellitus. Pharmacotherapy. 2013; 33(9): 984–999p. doi:10.1002/phar. 1303

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352(9131): 854–865p; Erratum in: Lancet. 1998; 352(9139): 1558p. doi:10.1016/S0140-6736(98)07037-8

Siraj ES, Rubin DJ, Riddle MC, Miller ME, Hsu FC, Ismail-Beigi F, Chen SH, Ambrosius WT, Thomas A, Bestermann W, Buse JB, Genuth S, Joyce C, Kovacs CS, Sigal RJ, Soloman S. Insulin dose and cardiovascular mortality in the ACCORD trial. Diabetes Care. 2015; 38(11): 2000–2008p. doi:10.2337/dc15-0598.

Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002; 51(3): 5368–5376p. doi:10.2337/diabetes.51.2007.S368.

Adrienne SA. Type 2 Diabetes Statistics and Facts. Healthline (Healthline Media) [Internet]; 2014 September 8. Available from: https://www.healthline.com/health/type-2-diabetes/statistics# Prevention

Centers for Disease Control and Prevention. Diabetes Latest. USA: CDC; 2014. Available from: https://search.cdc.gov/search/?query=Diabetes%20Latest.&dpage=1

Standards of medical care in diabetes-2016: summary of revisions. Diabetes Care. 2016; 39(Suppl 1): S4–S5. doi:10.2337/dc16-S003.

International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels, Belgium: International Diabetes Federation; 2011. Available from: https://fmdiabetes.org/wp-content/uploads/2022/01/ IDF_Atlas_10th_Edition_2021-comprimido.pdf (accessed on 2013 Nov 9).

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995; 44(11): 1249–1258p. Erratum in: Diabetes 1996; 45(11): 1655p. PMID: 7589820.

Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4): 773–795p. doi: 10.2337/db09-9028. PMID: 19336687; PMCID: PMC2661582.

UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9178): 837–853p.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577–1589p.

Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011; 378(9786): 182–197p.

Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism. 2011; 60(1): 1–23p.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Feranninni E, Nauck M, Peters AL, Tsapas A, Wender R, Methews DR. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55(6): 1577–1596p.




DOI: https://doi.org/10.37591/rrjom.v13i2.3274

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Research & Reviews: Journal of Medicine